
The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.
In this podcast, Brian Wojciechowski, MD, Breastcancer.org medical adviser, discusses some of the research that was published in July 2014.
In this podcast, Brian Wojciechowski, M.D., Breastcancer.org medical adviser, discusses some of the research that was published in July 2014. Listen to the podcast to hear Dr. Wojciechowski talk about:
Running time: 20:50






